Ariad Pharmaceuticals, Inc. (ARIA) - Financial and Strategic SWOT
Analysis Review
Reference Code: GDPH61132FSA Publication Date: MAR 2012
26 Landsdowne Street Phone +1 617 4940400 Revenue 25.3 (million USD)
Cambridge, MA Fax +1 617 4948144 Net Profit -123.60 (million USD)
02139-4234 Website www.ariad.com Employees 150
Pharmaceuticals &
United States Exchange ARIA [NASDAQ] Industry
Healthcare
Company Overview
Ariad Pharmaceuticals Inc (ARIAD) is a biopharmaceutical company discovering, developing and marketing small-molecule
oncology therapies. The company is focused on developing small-molecule drugs that treat solid tumors and hematologic
cancers. ARIAD 's product portfolio comprises four molecules including ridaforolimus (previously known as deforolimus), a
potent inhibitor in cancer cells, ponatinib (previously known as AP24534), a novel oral multi-targeted kinase inhibitor that has
broad potential applications in hematological cancers and solid tumors, AP26113, an anaplastic lymphoma kinase inhibitor and
AP1903.
Key Executives SWOT Analysis
Name Title Ariad Pharmaceuticals, Inc., SWOT Analysis
Dr. Harvey J. Berger, M.D. Chairman Strengths Weaknesses
Jay R. LaMarche Director
Collaboration with Merck History of Operating Losses
Dr. Athanase Lavidas, Director
Ph.D. Intellectual Property No Product Revenues
Dr. Massimo Radaelli, Director
Ph.D. Opportunities Threats
Wayne Wilson Director
Potential Market for Cancer Tightening of FDA’s Regulatory
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData Therapies Oversight
Share Data Rising Healthcare Expenditure Uncertain R&D Outcomes
in the US
Ariad Pharmaceuticals, Inc.
Share Price (USD) as on 23-Mar- 15.72
2012 Source: Annual Report, Company Website, Primary and Secondary Research,
GlobalData
EPS (USD) -0.93
Market Cap (million USD) 2,427
Enterprise Value (million USD) 2,133
Shares Outstanding (million) 159
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
Financial Performance Recent Developments
Feb 28, 2012 Ariad Reports Q4 2011 Results
Jan 03, 2012 ARIAD Pharmaceuticals To Trade On
NASDAQ Global Select Market
Nov 03, 2011 Ariad Pharmaceuticals Reports Revenue Of
$25.1m In Q3 2011
Sep 22, 2011 ARIAD To Present At Jefferies 2011 Global
Healthcare Conference In London
Source: Annual Report, Company Website, Primary and Secondary Research,
GlobalData
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
Ariad Pharmaceuticals, Inc. (ARIA) - Financial and Strategic SWOT Reference Code: GDPH61132FSA
Analysis Review
Source : www.globalcompanyintelligence.com Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables .................................................................................................................................................................................. 4
List of Figures ................................................................................................................................................................................. 4
Section 1 - About the Company.......................................................................................................................................................... 5
Ariad Pharmaceuticals, Inc. - Key Facts ............................................................................................................................................. 5
Ariad Pharmaceuticals, Inc. - Key Employees .................................................................................................................................... 6
Ariad Pharmaceuticals, Inc. - Key Employee Biographies .................................................................................................................. 7
Ariad Pharmaceuticals, Inc. - Major Products and Services ............................................................................................................... 9
Ariad Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data............................................................................................. 10
Ariad Pharmaceuticals, Inc., Pipeline Products by Therapy Area ................................................................................................. 10
Ariad Pharmaceuticals, Inc., Pipeline Products by Development Phase....................................................................................... 11
Ariad Pharmaceuticals, Inc. - History ............................................................................................................................................... 13
Ariad Pharmaceuticals, Inc. - Company Statement .......................................................................................................................... 15
Ariad Pharmaceuticals, Inc. - Locations And Subsidiaries................................................................................................................ 27
Head Office ................................................................................................................................................................................... 27
Other Locations & Subsidiaries ..................................................................................................................................................... 27
Section 2 – Company Analysis ......................................................................................................................................................... 28
Ariad Pharmaceuticals, Inc. - Business Description ......................................................................................................................... 28
Ariad Pharmaceuticals, Inc. - Corporate Strategy ............................................................................................................................ 29
Ariad Pharmaceuticals, Inc. - SWOT Analysis.................................................................................................................................. 30
SWOT Analysis - Overview........................................................................................................................................................... 30
Ariad Pharmaceuticals, Inc. - Strengths ........................................................................................................................................ 30
Strength - Collaboration with Merck .......................................................................................................................................... 30
Strength - Intellectual Property .................................................................................................................................................. 30
Strength - Orphan Drug Designation - ponatinib ...................................................................................................................... 30
Ariad Pharmaceuticals, Inc. - Weaknesses................................................................................................................................... 31
Weakness - History of Operating Losses .................................................................................................................................. 31
Weakness - No Product Revenues ........................................................................................................................................... 31
Ariad Pharmaceuticals, Inc. - Opportunities .................................................................................................................................. 31
Opportunity - Potential Market for Cancer Therapies ................................................................................................................ 31
Opportunity - Rising Healthcare Expenditure in the US............................................................................................................. 31
Opportunity - Robust Oncology Product Pipeline ...................................................................................................................... 31
Ariad Pharmaceuticals, Inc. - Threats ........................................................................................................................................... 32
Threat - Tightening of FDA’s Regulatory Oversight ................................................................................................................... 32
Threat - Uncertain R&D Outcomes ........................................................................................................................................... 32
Threat - Competitive Pressures ................................................................................................................................................. 32
Ariad Pharmaceuticals, Inc. - Key Competitors ................................................................................................................................ 33
Section 3 – Company Financial Ratios ............................................................................................................................................. 34
Financial Ratios - Capital Market Ratios........................................................................................................................................... 34
Financial Ratios - Annual Ratios ...................................................................................................................................................... 34
Performance Chart ........................................................................................................................................................................... 36
Financial Performance...................................................................................................................................................................... 36
Financial Ratios - Interim Ratios....................................................................................................................................................... 37
Financial Ratios - Ratio Charts ......................................................................................................................................................... 38
Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 39
Ariad Pharmaceuticals, Inc. (ARIA) - Financial and Strategic SWOT Reference Code: GDPH61132FSA
Analysis Review
Source : www.globalcompanyintelligence.com Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 ................................................ 39
Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 ................................................ 40
Ariad Pharmaceuticals, Inc., Recent Deals Summary ...................................................................................................................... 41
Section 5 – Company’s Recent Developments ................................................................................................................................ 42
Ariad Pharmaceuticals, Inc., Recent Developments ..................................................................................................................... 42
Feb 28, 2012: Ariad Reports Q4 2011 Results .......................................................................................................................... 42
Jan 03, 2012: ARIAD Pharmaceuticals To Trade On NASDAQ Global Select Market .............................................................. 43
Nov 03, 2011: Ariad Pharmaceuticals Reports Revenue Of $25.1m In Q3 2011 ...................................................................... 44
Sep 22, 2011: ARIAD To Present At Jefferies 2011 Global Healthcare Conference In London ................................................ 44
Sep 06, 2011: ARIAD Appoints Martin Duvall As Senior Vice President Commercial Operations ............................................ 44
Aug 02, 2011: Ariad Reports Q2 2011 Financial Results .......................................................................................................... 45
May 04, 2011: ARIAD Pharmaceuticals Reports Net Loss Of $37.9m For Q1 2011 ................................................................. 46
May 02, 2011: ARIAD Pharmaceuticals Names Norbert Riedel To Board ................................................................................ 47
Feb 17, 2011: ARIAD Reports Net Loss Of $30.3m For Q4 2010 ............................................................................................. 47
Section 6 – Appendix ...................................................